171 related articles for article (PubMed ID: 24590773)
21. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
[TBL] [Abstract][Full Text] [Related]
23. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
[TBL] [Abstract][Full Text] [Related]
24. CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.
Baatjes K; Peeters A; McCaul M; Conradie MM; Apffelstaedt J; Conradie M; Kotze MJ
Curr Pharm Des; 2020; 26(46):6007-6012. PubMed ID: 32900345
[TBL] [Abstract][Full Text] [Related]
25. [Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor].
Du ZG; Wang LY; Zhou Y; Wan HY; Liang FQ; Lyu Q
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):827-832. PubMed ID: 30107717
[No Abstract] [Full Text] [Related]
26. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
27. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q
PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenomics of third-generation aromatase inhibitors.
Turkistani A; Marsh S
Expert Opin Pharmacother; 2012 Jun; 13(9):1299-307. PubMed ID: 22594760
[TBL] [Abstract][Full Text] [Related]
29. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
Colomer R; Monzo M; Tusquets I; Rifa J; Baena JM; Barnadas A; Calvo L; Carabantes F; Crespo C; Muñoz M; Llombart A; Plazaola A; Artells R; Gilabert M; Lloveras B; Alba E
Clin Cancer Res; 2008 Feb; 14(3):811-6. PubMed ID: 18245543
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
[TBL] [Abstract][Full Text] [Related]
31. Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Friesenhengst A; Pribitzer-Winner T; Miedl H; Pröstling K; Schreiber M
Horm Cancer; 2018 Apr; 9(2):128-138. PubMed ID: 29363090
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
[TBL] [Abstract][Full Text] [Related]
33. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
34. Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
Cai Q; Kataoka N; Li C; Wen W; Smith JR; Gao YT; Shu XO; Zheng W
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):27-32. PubMed ID: 18199708
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant aromatase inhibitor therapy in patients with stage I breast cancer at a regional oncology center in Israel: implementation of a 'switching' policy in postmenopausal patients after initial tamoxifen.
Geffen DB; Tokar M; Abu-Ghanem S; Braunstein R; Koretz M; Amir N; Delgado B; Sion-Vardi N; Ariad S; Lazarev I
Oncology; 2013; 85(3):145-52. PubMed ID: 23988814
[TBL] [Abstract][Full Text] [Related]
37. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
38. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
[TBL] [Abstract][Full Text] [Related]
40. Aromatase inhibitors in the treatment of early and advanced breast cancer.
Joensuu H; Ejlertsen B; Lønning PE; Rutqvist LE
Acta Oncol; 2005; 44(1):23-31. PubMed ID: 15848903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]